KRAS mutation is highly predictive of cetuximab resistance in metastatic colorectal cancer

被引：0
|
作者：
Di Fiore, F. [1 ]
Le Pessot, F. [1 ]
Lamy, A. [1 ]
Charbonnier, F. [1 ]
Sabourin, J. [1 ]
Paillot, B. [1 ]
Frebourg, T. [1 ]
Michel, P. [1 ]
机构：
[1] Rouen Univ Hosp, INSERM, U 614, Rouen, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10502
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The role of KRAS, BRAF, and PI3K mutations as markers of resistance to cetuximab in metastatic colorectal cancer
    Passardi, A.
    Ulivi, P.
    Valgiusti, M.
    Scarpi, E.
    Moscati, R.
    Chiadini, E.
    Rosetti, P.
    Saragoni, L.
    Capelli, L.
    Gardini, A. Casadei
    Ragazzini, A.
    Monti, M.
    Calpona, S.
    Zoli, W.
    Milandri, C.
    Frassineti, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer
    Pinto, Pedro
    Rocha, Patricia
    Veiga, Isabel
    Guedes, Joana
    Pinheiro, Manuela
    Peixoto, Ana
    Pinto, Carla
    Fragoso, Maria
    Sanches, Evaristo
    Araujo, Antonio
    Alves, Fernando
    Coutinho, Camila
    Lopes, Paula
    Henrique, Rui
    Teixeira, Manuel R.
    CANCER GENETICS, 2011, 204 (08) : 439 - 446
  • [23] Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Ciardiello, Fortunato
    Tejpar, Sabine
    Papamichael, Demetris
    TARGETED ONCOLOGY, 2009, 4 (04) : 311 - 322
  • [24] Implications of KRAS mutation status for the treatment of metastatic colorectal cancer
    Fortunato Ciardiello
    Sabine Tejpar
    Demetris Papamichael
    Targeted Oncology, 2009, 4 : 311 - 322
  • [25] Impact of KRAS Mutation on Outcome of Patients with Metastatic Colorectal Cancer
    Chang, Yu-Yao
    Lin, Jen-Kou
    Lin, Tzu-Chen
    Chen, Wei-Shone
    Jiang, Jeng-Kai
    Yang, Shung-Haur
    Wang, Huann-Sheng
    Lan, Yuan-Tzu
    Lin, Chun-Chi
    Liang, Wen-Yih
    Chang, Shih-Ching
    HEPATO-GASTROENTEROLOGY, 2014, 61 (135) : 1946 - 1953
  • [26] The secondary mutation of KRAS and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer
    Xia, X.
    Du, W.
    Zhu, Y.
    Bai, Y.
    Liu, M.
    CLINICAL & EXPERIMENTAL METASTASIS, 2017, 34 (3-4) : 218 - 218
  • [27] Cetuximab in metastatic colorectal cancer
    Broadbridge, Vy Tuong
    Karapetis, Cristos S.
    Price, Timothy Jay
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (05) : 555 - 565
  • [28] Cetuximab for metastatic colorectal cancer
    Sharma, Sharan Prakash
    LANCET ONCOLOGY, 2007, 8 (08): : 673 - 673
  • [29] Cetuximab in metastatic colorectal cancer
    Wolf, Ido
    Golan, Talia
    Shani, Adi
    Aderka, Dan
    LANCET ONCOLOGY, 2010, 11 (04): : 313 - 314
  • [30] Predictive biomarkers of response to cetuximab in Chinese patients with metastatic colorectal cancer
    Ma, Brigette
    Loong, Herbert
    Liem, Giok Siong
    Mo, Frankie
    Tong, Joanna
    Wong, S. C. Cesar
    Chan, Anthony T. C.
    To, Ka Fai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345